Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.

Hovione Scientia Ltd. is a private company headquartered in Ireland that manufactures pharmaceutical products.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

BioPharmX, Inc. provides innovative drug-delivery products through its unique, patented platform technologies for pharmaceutical and OTC applications. Its products are designed to address unmet needs in large, well-defined and under-served markets in the fast growing health and wellness markets, including dermatology, women's health and Ear, Nose and Throat (ENT) therapy. The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep bio-tech expertise focused on drug delivery and molecular properties. Technical expertise includes pharmaceutical, biological sciences, medical devices and consumer product development with extensive experience in ex vivo/in vitro design, preclinical and clinical development, as well as intellectual property generation. Quality and regulatory expertise includes knowledge of medical directives, US FDA guidance for drugs and medical devices and ICH & IEC guidelines for the US, Canada. China and European Union.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Laboratory Skin Care is a biotechnology company committed to the development of Dermal Delivery Technologies.

American Cyanamid Company was a U.S.-based diversified company with businesses in several fields. The company was a manufacturer of agricultural chemicals, cosmetics, perfumes, building products, plastics and pharmaceuticals. The company was listed as a top 100 manufacturing company by Fortune magazine in the 1970s. Cyanamid was founded in 1907 and employed over 100,000 people around the world by 2000. The company maintained a monopoly over tetracycline, an antibiotic used against bacterial infections. A theft of the organism led to the loss of the monopoly as rival companies were able to produce generic versions of the formula, leading to huge losses to the company. The company sold most of its businesses in the early 2000s and is now operated under the name Cytec.  

Their attorneys are no-nonsense, get-to-the-root-of-the-problem kind of people. If there’s a faster way to get there, they’ll find it. It’s their job to give you clear answers and sound solutions. They focus on what matters to you — whether it’s overcoming a legal challenge, taking your business to the next level, or having a trusted partner for ongoing legal advice. Think of us as an extension of your team with the legal know-how, connections, and industry experience to safeguard your interests. It’s also their job to make sure you are meeting the people you need to know. They have a network of some of the sharpest business leaders, money people, and legal minds on the planet. Their attorneys are always looking for ways to leverage their resources on clients’ behalf. They help you move your agenda forward and deal effectively and efficiently with obstacles that come between you and your goals. Responsive, aggressive problem-solving is a Mintz Levin hallmark and the foundation of the firm’s success and growth since 1933.

Medicis Pharmaceutical Corp. develops and markets pharmaceutical products for dermatological usages. It offers a broad range of products addressing various conditions or aesthetic improvements, including facial wrinkles, glabellar lines, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis and cosmesis. The company was founded on July 28, 1988 and is headquartered in Phoenix, AZ.

Tepha is a medical device firm pursuing the development and commercialization of innovative products based on the company's proprietary biomaterial technology. The technology provides a new class of absorbable biomaterials, known as polyhydroxyalkanoates , which may be tailored to meet unmet needs for medical devices in multiple fields. Tepha's novel, biosynthetically produced materials offer superior performance in flexibility, elasticity, and biocompatibility; and, for its fiber-based products, excellent tensile strength and strength retention.

Part of Hovione Farmaci��ncia SA, Hovione Inter AG is a company headquartered in Lucerne, Switzerland, that trades pharmaceutical products.

Part of Pfizer Inc., Wyeth Lederle Japan Ltd is a company headquartered in Tokyo, Japan, specializing in pharmaceutical preparations. Wyeth Corp., now a subsidiary of Pfizer Inc. acquired Wyeth Lederle Japan Ltd from Takeda Pharmaceutical Co., Ltd. on May 21, 2003.

NeuMedics was founded in Washington State in 2008. It is a development stage biopharmaceutical company focused on the rapid development of therapies to treat Diabetic Macular Edema (DME) and related inflammatory conditions.

Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal.

Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Over the decades, we have established ourselves as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) and NBEs (New Biological Entity). They have several molecules in various stages of pre-clinical and clinical development and are primarily focused in the areas of Oncology, Respiratory and Dermatology.

Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. Ethicon has manufactured surgical sutures and wound closure devices since 1887. After World War II, Ethicon's market share in surgical sutures rose from 15% to 70% worldwide. In the United States, the market share is approximately 80%.